APOC4

Across TCGA pan-cancer cohorts, APOC4 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated APOC4 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher APOC4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated APOC4 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

LUAD, LSCC, and GBM are the cancer types where APOC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.643	0.996	.012	35	view →
LSCC	DFS	Median	II,III,IV	0.820	1.000	.003	26	view →
GBM	DFS	Tertile	All	0.581	0.221	<.001	19	view →
HNSC	OS	Quartile	All	0.855	0.605	.005	10	view →
CCRCC	DFS	Median	All	0.891	0.629	.012	8	view →
UCEC	DFS	Quartile	All	0.805	0.972	.032	2	view →
PDAC	DFS	Tertile	All	0.754	0.871	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

APOC4–LUAD (OS)

Open the LUAD breakdown →